Starpharma Holdings Limited (SPL:ASX)


right-arrow Created with Sketch. -0.075 (-5.51%)
MCAP $521.8M
Last trade 16.10pm 28/07/2021 20mins delayed

Latest Announcements

10.37am 28/07/2021SPLStarpharma Holdings Limited
27/07/2021SPLStarpharma Holdings Limited
27/07/2021 Price SensitivePSSPLStarpharma Holdings Limited
05/07/2021SPLStarpharma Holdings Limited
02/07/2021SPLStarpharma Holdings Limited
24/06/2021SPLStarpharma Holdings Limited
21/06/2021 Price SensitivePSSPLStarpharma Holdings Limited
18/06/2021 Price SensitivePSSPLStarpharma Holdings Limited

Company Overview

Starpharma Holdings Limited is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The Company utilizes dendrimers, which is a type of synthetic nanoscale polymer that is regular in size and structure and suited to pharmaceutical and medical uses. The Company’s development programs, including VivaGel portfolio and DEP drug delivery. The Company’s DEP drug delivery, which includes DEP docetaxel, DEP cabazitaxel, DEP irinotecan and Targeted-DEP. It develops and commercializes dendrimer nanotechnology across various applications, including sexual health, drug delivery for pharmaceuticals, animal health, coatings and inks, crop protection, diagnostics and research reagents, cosmetics and water treatment. Its products are based on VivaGel (SPL7013, astodrimer sodium), a dendrimer, which has antimicrobial properties. It has both partnered and internal programs in drug delivery.

SPL in the news

Search Previous Announcements